The company's 2024 Sustainability Report highlights emissions reduction and progress toward its CN2030 goals
MELVILLE, N.Y., June 26, 2025 /PRNewswire/ -- Leviton today announced significant progress towards its goal of achieving company-wide carbon neutrality by 2030 in its 2024 Sustainability Report. The report reveals a 37% reduction in overall greenhouse gas (GHG) emissions or CO2e (carbon dioxide equivalent) from a 2021 baseline. As part of Leviton's CN2030 program, the company has steadily moved towards renewable and clean energy providers and has made investments in certified carbon offset projects for remaining residual emissions.
"The significant progress we've made with our CN2030 program is a testament to the dedication and collective effort of our employees around the world and we're not finished," said Daryoush Larizadeh, Leviton's president and CEO. "As a leader in lighting, powering and connecting everyday spaces, we recognize our responsibility to not only lower our CO2e emissions but enable our customers to do the same."
Leviton's CN2030 program, announced in 2022, includes an ambitious goal of achieving company-wide carbon neutrality by 2030. Details on the company's CN2030 progress and other achievements in fiscal year 2024 are included in its third annual sustainability report. Additional highlights include:
- Achieved an 11% year-over-year reduction in CO2e emissions from 2023 to 2024.
- Reached carbon neutrality at 19 company sites.
- Expanded the Sustainably Smart Packaging program to further reduce jobsite waste.
- Launched a new Zero Waste to Landfill program.
- Leviton's Camargo, Mexico facility, which underwent a recent expansion, earned The Green Building Initiative (GBI) Green Globe® certification, making it the first GBI Green Globe certification in Mexico.
- Increased the number of Network Solutions products with Environmental Product Declarations (EPDs).
"Sustainability is a priority for our company, and the results to-date speak for themselves," said Ross Goldman, Leviton's Chief Sustainability Officer and COO of Leviton's Network Solutions business unit. "I am proud of all our employees and partners who contribute to making our CN2030 program successful. I am incredibly excited to continue making strides toward a carbon neutral future."
To explore Leviton's full sustainability strategy and achievements, view the 2024 Sustainability Report at leviton.com/sustainability. For more information about Leviton's products and services, visit leviton.com.
About Leviton
Every day, Leviton builds what's next to light, power, and connect everyday spaces to meet the needs of its residential, commercial, and industrial customers globally. From controls, to lighting, to electrical, to networking, Leviton's relentless innovation for more than a century enables our customers' lives to be easier, safer, more efficient, productive and sustainable. Driven by its commitment to its customers, the ingenuity of its employees, and the safety and quality of its products and solutions, with Leviton, the FUTURE IS ON. For more information, visit leviton.com,facebook.com/leviton, twitter.com/leviton, or youtube.com/levitonmfg.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Leviton Reduces GHG Emissions by 37% since 2021, Advancing toward Carbon Neutrality by 2030
Leviton Reduces GHG Emissions by 37% since 2021, Advancing toward Carbon Neutrality by 2030
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
